Effects of quetiapine on cognitive functions in schizophrenia

Akdede B. B., ALPTEKİN K., Kitis A., Arkar H., Akvardar Y.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, cilt.29, sa.2, ss.233-238, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29 Sayı: 2
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1016/j.pnpbp.2004.11.005
  • Dergi Adı: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.233-238
  • Anahtar Kelimeler: cognitive function, quetiapine, schizophrenia, SYNDROME SCALE PANSS, NEUROPSYCHOLOGICAL DEFICITS, HALOPERIDOL, RISPERIDONE, CLOZAPINE, OLANZAPINE, ANTIPSYCHOTICS, IMPROVEMENT, FUMARATE, SEROQUEL
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: All atypical antipsychotic drugs with complex pharmacology have been shown to improve some, but not all, domains of cognitive function, including quetiapine, i.e., the agent with the most rapid dissociation from dopamine receptors and a relatively weak serotonin antagonism. The present study was to evaluate which, if any, areas of cognition improve in patients with schizophrenia, following a brief treatment with quetiapine.